N1-PhenylsuberamideCAS# 1305124-48-4 |
Quality Control & MSDS
3D structure
Package In Stock
Number of papers citing our products
| Cas No. | 1305124-48-4 | SDF | Download SDF |
| PubChem ID | 23075284 | Appearance | Powder |
| Formula | C14H20N2O2 | M.Wt | 248.32 |
| Type of Compound | Alkaloids | Storage | Desiccate at -20°C |
| Solubility | Soluble in Chloroform,Dichloromethane,Ethyl Acetate,DMSO,Acetone,etc. | ||
| Chemical Name | N'-phenyloctanediamide | ||
| SMILES | C1=CC=C(C=C1)NC(=O)CCCCCCC(=O)N | ||
| Standard InChIKey | FYALHEGRKUJDBE-UHFFFAOYSA-N | ||
| Standard InChI | InChI=1S/C14H20N2O2/c15-13(17)10-6-1-2-7-11-14(18)16-12-8-4-3-5-9-12/h3-5,8-9H,1-2,6-7,10-11H2,(H2,15,17)(H,16,18) | ||
| General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months. Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it. |
||
| About Packaging | 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial. 2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial. 3. Try to avoid loss or contamination during the experiment. |
||
| Shipping Condition | Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request. | ||
N1-Phenylsuberamide Dilution Calculator
N1-Phenylsuberamide Molarity Calculator
| 1 mg | 5 mg | 10 mg | 20 mg | 25 mg | |
| 1 mM | 4.0271 mL | 20.1353 mL | 40.2706 mL | 80.5412 mL | 100.6765 mL |
| 5 mM | 0.8054 mL | 4.0271 mL | 8.0541 mL | 16.1082 mL | 20.1353 mL |
| 10 mM | 0.4027 mL | 2.0135 mL | 4.0271 mL | 8.0541 mL | 10.0677 mL |
| 50 mM | 0.0805 mL | 0.4027 mL | 0.8054 mL | 1.6108 mL | 2.0135 mL |
| 100 mM | 0.0403 mL | 0.2014 mL | 0.4027 mL | 0.8054 mL | 1.0068 mL |
| * Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations. | |||||
Calcutta University
University of Minnesota
University of Maryland School of Medicine
University of Illinois at Chicago
The Ohio State University
University of Zurich
Harvard University
Colorado State University
Auburn University
Yale University
Worcester Polytechnic Institute
Washington State University
Stanford University
University of Leipzig
Universidade da Beira Interior
The Institute of Cancer Research
Heidelberg University
University of Amsterdam
University of Auckland
TsingHua University
The University of Michigan
Miami University
DRURY University
Jilin University
Fudan University
Wuhan University
Sun Yat-sen University
Universite de Paris
Deemed University
Auckland University
The University of Tokyo
Korea University
- Suberanilic acid
Catalog No.:BCX0406
CAS No.:149648-52-2
- Kaempferol 7-O-(4''-O-methyl)glucoside
Catalog No.:BCX0405
CAS No.:1092795-48-6
- 3''-Methoxycentrolobol
Catalog No.:BCX0404
CAS No.:811471-19-9
- Ichanexic acid
Catalog No.:BCX0403
CAS No.:1044818-57-6
- Disporopsin 4'-methyl ether
Catalog No.:BCX0402
CAS No.:1671098-53-5
- 8-Methyl-2'-deoxydisporopsin
Catalog No.:BCX0401
CAS No.:1671098-52-4
- 8-Methyldisporopsin 4'-methyl ether
Catalog No.:BCX0400
CAS No.:1589545-88-9
- 8-Methyldisporopsin
Catalog No.:BCX0399
CAS No.:1671098-51-3
- Disporopsin
Catalog No.:BCX0398
CAS No.:1430334-05-6
- 6-Aminoquinolyl-N-hydroxysuccinimidyl carbamate
Catalog No.:BCX0397
CAS No.:148757-94-2
- 17α-Deacetyltanghinin
Catalog No.:BCX0396
CAS No.:111614-46-1
- Levulinic acid
Catalog No.:BCX0395
CAS No.:123-76-2
- Andrographidine G
Catalog No.:BCX0408
CAS No.:1494685-00-5
- Bisandrographolide G
Catalog No.:BCX0409
CAS No.:2699680-69-6
- Diplacol
Catalog No.:BCX0410
CAS No.:76556-05-3
- 4''-O-Glucosyl-17β-deacetyltanghinin
Catalog No.:BCX0411
CAS No.:114613-60-4
- 6''-O-(3-Hydroxy-3-methylglutaroyl)astragalin
Catalog No.:BCX0412
CAS No.:157407-84-6
- 12α-Methoxyabietic acid
Catalog No.:BCX0413
CAS No.:83905-80-0
- 4-(5-Oxotetrahydrofuran-2-yl)-N-phenylbutanamide
Catalog No.:BCX0414
CAS No.:100718-44-3
- (S)-5-Hydroxy-7-(4-hydroxy-3-methoxyphenyl)-1-(4-hydroxyphenyl)heptan-3-one
Catalog No.:BCX0415
CAS No.:619297-56-2
- 5,6,7,2'-Tetramethoxyisoflavone
Catalog No.:BCX0416
CAS No.:100211-04-9
- Nomilin 17-O-glucoside
Catalog No.:BCX0417
CAS No.:123564-62-5
- Lycoperodine 1
Catalog No.:BCX0418
CAS No.:6052-68-2
- 5α,6α-Epoxyergosta-8(14),22-diene-3β,7α-diol
Catalog No.:BCX0419
CAS No.:22259-18-3
Efficient new constructs against triple negative breast cancer cells: synthesis and preliminary biological study of ferrocifen-SAHA hybrids and related species.[Pubmed:24030275]
Dalton Trans. 2013 Nov 21;42(43):15489-501.
Chemotherapeutic agents combining several active groups within a single molecule can modulate multiple cellular pathways and, thus, exhibit higher efficacy than single-target drugs. In this study, six new hybrid compounds combining tamoxifen (TAM) or ferrocifen (FcTAM) structural motifs with suberoylanilide hydroxamic acid (SAHA) were synthesised and evaluated. Antiproliferative activity was first explored in cancer cell lines. Combining FcTAM and SAHA structural motifs to form the unprecedented FcTAM-SAHA hybrid molecule led to an increased cytotoxicity (IC50 = 0.7 muM) in triple-negative MDA-MB-231 breast cancer cells when compared to FcTAM or SAHA alone (IC50 = 2.6 muM and 3.6 muM, respectively), while the organic hybrid analogue TAM-SAHA was far less cytotoxic (IC50 = 8.6 muM). In hormone-dependent MCF-7 breast cancer cells, FcTAM-SAHA was more active (IC50 = 2.0 muM) than FcTAM (IC50 = 4.4 muM) and TAM-SAHA (IC50 > 10 muM), but less toxic than SAHA (IC50 = 1.0 muM). Surprisingly, FcTAM-PSA, an N1-Phenylsuberamide derivative, also possessed strong antiproliferative activity (IC50 = 0.5 muM and 1.8 muM in MDA-MB-231 and MCF-7 cells, respectively). Subsequent biochemical studies indicate that estrogen receptor alpha (ERalpha) and histone deacetylases (HDAC) are not the main targets of the hybrid compounds for their antiproliferative effect. Interestingly, both organometallic compounds were able to induce p21waf1/cip1 gene expression in MCF-7 breast cancer cells in accordance with their antiproliferative activity.
